127 related articles for article (PubMed ID: 30111966)
21. Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans.
Salek S; Lussier Hoskyn S; Johns JR; Allen N; Sehgal C
Front Pharmacol; 2019; 10():196. PubMed ID: 30983993
[TBL] [Abstract][Full Text] [Related]
22. The public funding of expensive cancer therapies: synthesizing the "3Es"--evidence, economics, and ethics.
Kirby J; Somers E; Simpson C; McPhee J
Organ Ethic; 2008; 4(2):97-108. PubMed ID: 18839752
[TBL] [Abstract][Full Text] [Related]
23. Not All Canadian Cancer Patients Are Equal-Disparities in Public Cancer Drug Funding across Canada.
MacPhail C; Snow S
Curr Oncol; 2022 Mar; 29(3):2064-2072. PubMed ID: 35323366
[TBL] [Abstract][Full Text] [Related]
24. Are We Making a Difference? A Qualitative Study of Patient Engagement at the pan-Canadian Oncology Drug Review: Perspectives of Patient Groups.
Mercer RE; Chambers A; Mai H; McDonald V; McMahon C; Chan KKW
Value Health; 2020 Sep; 23(9):1157-1162. PubMed ID: 32940233
[TBL] [Abstract][Full Text] [Related]
25. Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications.
Salek SM; Lussier Hoskyn S; Johns J; Allen N; Sehgal C
Front Pharmacol; 2018; 9():1578. PubMed ID: 30833899
[TBL] [Abstract][Full Text] [Related]
26. Access to drugs for cancer: Does where you live matter?
Menon D; Stafinski T; Stuart G
Can J Public Health; 2005; 96(6):454-8. PubMed ID: 16350873
[TBL] [Abstract][Full Text] [Related]
27. The timing of drug funding announcements relative to elections: a case study involving dementia medications.
Gill SS; Gupta N; Bell CM; Rochon PA; Austin PC; Laupacis A
PLoS One; 2013; 8(2):e56921. PubMed ID: 23460820
[TBL] [Abstract][Full Text] [Related]
28. Value assessment of oncology drugs using a weighted criterion-based approach.
Ezeife DA; Dionne F; Fares AF; Cusano ELR; Fazelzad R; Ng W; Husereau D; Ali F; Sit C; Stein B; Law JH; Le L; Ellis PM; Berry S; Peacock S; Mitton C; Earle CC; Chan KKW; Leighl NB
Cancer; 2020 Apr; 126(7):1530-1540. PubMed ID: 31860138
[TBL] [Abstract][Full Text] [Related]
29. Use of product listing agreements by Canadian provincial drug benefit plans.
Morgan SG; Friesen MK; Thomson PA; Daw JR
Healthc Policy; 2013 May; 8(4):45-55. PubMed ID: 23968637
[TBL] [Abstract][Full Text] [Related]
30. Impact of rarity on Canadian oncology health technology assessment and funding.
Keech J; Dai WF; Trudeau M; Mercer RE; Naipaul R; Wright FC; Ferguson SE; Darling G; Gavura S; Eisen A; Kouroukis CT; Beca J; Chan KKW
Int J Technol Assess Health Care; 2020 Aug; ():1-6. PubMed ID: 32779560
[TBL] [Abstract][Full Text] [Related]
31. Pricing of alcohol in Canada: A comparison of provincial policies and harm-reduction opportunities.
Giesbrecht N; Wettlaufer A; Thomas G; Stockwell T; Thompson K; April N; Asbridge M; Cukier S; Mann R; McAllister J; Murie A; Pauley C; Plamondon L; Vallance K
Drug Alcohol Rev; 2016 May; 35(3):289-97. PubMed ID: 26530717
[TBL] [Abstract][Full Text] [Related]
32. "There is always a better way": Managing uncertainty in decision making about new cancer drugs in Canada.
Driedger SM; Cooper E; Annable G; Brouwers M
Int J Health Plann Manage; 2018 Apr; 33(2):e485-e499. PubMed ID: 29417619
[TBL] [Abstract][Full Text] [Related]
33. Clinician Perspectives of COVID-19-Related Cancer Drug Funding Measures in Ontario.
Naipaul RD; Mercer RE; Chan KKW; Yeung L; Forbes L; Gavura S
Curr Oncol; 2021 Feb; 28(2):1056-1066. PubMed ID: 33652898
[TBL] [Abstract][Full Text] [Related]
34. How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma.
Chabot I; Rocchi A
Value Health; 2010; 13(6):837-45. PubMed ID: 20561332
[TBL] [Abstract][Full Text] [Related]
35. Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study.
Lexchin J
PLoS One; 2019; 14(2):e0212399. PubMed ID: 30768629
[TBL] [Abstract][Full Text] [Related]
36. Engaging the Canadian public on reimbursement decision-making for drugs for rare diseases: a national online survey.
Polisena J; Burgess M; Mitton C; Lynd LD
BMC Health Serv Res; 2017 May; 17(1):372. PubMed ID: 28549479
[TBL] [Abstract][Full Text] [Related]
37. Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis.
Lexchin J
BMJ Open; 2017 Oct; 7(10):e018372. PubMed ID: 29061631
[TBL] [Abstract][Full Text] [Related]
38. Milestones, barriers and beacons: Shared decision making in Canada inches ahead.
Légaré F; Stacey D; Forest PG; Coutu MF; Archambault P; Boland L; Witteman HO; LeBlanc A; Lewis KB; Giguere AMC
Z Evid Fortbild Qual Gesundhwes; 2017 Jun; 123-124():23-27. PubMed ID: 28532628
[TBL] [Abstract][Full Text] [Related]
39. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
[TBL] [Abstract][Full Text] [Related]
40. Meaningful patient representation informing Canada's cancer drug funding decisions: views of patient representatives on the Pan-Canadian Oncology Drug Review.
Hoch JS; Brown MB; McMahon C; Nanson J; Rozmovits L
Curr Oncol; 2014 Oct; 21(5):263-6. PubMed ID: 25302034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
